Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/18/2025

Management of COPD Exacerbations

Introduction to COPD Exacerbation Management

  • The European Respiratory Society (ERS) and the American Thoracic Society (ATS) recommend a therapeutic approach based on bronchodilators, corticosteroids, antibiotics, controlled oxygen therapy, and, in selected cases, non-invasive ventilation for managing COPD exacerbations 1
  • A COPD exacerbation is clinically defined as episodes of increased respiratory symptoms, particularly dyspnea, cough, sputum production, and increased sputum purulence 1

Assessment and Investigation

  • Signs suggesting significant deterioration include infection (fever, frankly purulent sputum), severe airway obstruction (audible wheezing, tachypnea, use of accessory muscles), peripheral edema, cyanosis, and confusion 2
  • Urgent investigations that should be performed include measurement of arterial blood gases, noting the concentration of inspired oxygen (FiO₂), chest radiography, full blood count, urea and electrolytes, ECG, and initial FEV1 and/or peak flow 2

Oxygen Therapy

  • In patients with a history of COPD over 50 years old, do not administer a FiO₂ greater than 28% via a Venturi mask or 2 L/min via nasal cannula until arterial blood gas tensions are known 2
  • Check blood gases within 60 minutes after starting oxygen and within 60 minutes after a change in inspired oxygen concentration 2
  • If the PaO₂ responds and the effect on pH is moderate, increase the inspired oxygen concentration until the PaO₂ is greater than 7.5 kPa 2

Pharmacological Management

  • Bronchodilators should be administered via nebulizer on arrival and at 4-6 hour intervals thereafter 2
  • For moderate exacerbations, a β-agonist (salbutamol 2.5-5 mg or terbutalina 5-10 mg) or an anticholinergic agent (ipratropium bromide 0.25-0.5 mg) should be used 2
  • For severe exacerbations or if the response to any treatment is deficient, both agents can be administered 2
  • The ERS/ATS recommends the use of oral corticosteroids to treat ambulatory patients with COPD exacerbation 1
  • The ERS/ATS also recommends the use of antibiotics to treat ambulatory patients with COPD exacerbation 1
  • Indicated if there are signs of infection (fever, frankly purulent sputum), common antibiotics such as amoxicillin or tetracycline are usually adequate 2

Non-Invasive Ventilation

  • The ERS/ATS recommends the use of non-invasive ventilation (NIV) in hospitalized patients with COPD exacerbation associated with acute or acute-on-chronic respiratory failure 1
  • A pH below 7.26 is predictive of a poor outcome 2

Rehabilitation and Follow-Up

  • The ERS/ATS recommends implementing a home management program (hospital at home) in patients with COPD exacerbations 1
  • The ERS/ATS makes a conditional recommendation for the implementation of pulmonary rehabilitation within 3 weeks after hospital discharge 1
  • Regular monitoring of symptoms, exacerbations, and objective measures of airflow limitation, as well as surveillance for signs of worsening right heart failure, is recommended 3
  • Reevaluation of oxygen requirements should be performed periodically 3
  • Annual influenza vaccination and pneumococcal vaccination every 5-10 years are recommended 3

Discharge and Post-Discharge Care

  • Bronchodilators should be continued for 24-48 hours or until the patient improves clinically 2
  • Corticosteroids should be discontinued after the acute episode, usually after 7-14 days of treatment 2
  • Consider pulmonary rehabilitation within 3 weeks after hospital discharge 1